Related Experiment Video
Updated: Aug 16, 2026

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
Published on: June 18, 2016
[The effect of histamine H2 receptor blockaders on the proteolytic activity in patients with ulcers]
Abstract:
Fifty-three patients with duodenal ulcer and chronic duodenitis and 8 normal subjects were examined for the proteolytic activity parameters in the duodenal cavity and in withdrawn duodenal contents. In 13 duodenal ulcer patients these parameters were examined before and after therapy with histadyl (histamine H2-receptor blocker). The findings evidence that intraduodenal proteolytic activity is lower in peptic ulcer than in health, whereas the digestion of protein substrate preincubated in the duodenal cavity and put into acid solution (pH 1.68) is active in the patients and absent in normal subjects. This latter parameter reduces in peptic ulcer patients under the effect of histadyl therapy.
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease II: Pathophysiology

